查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1923034

黏性补充剂注射市场按产品类型、应用部位、患者年龄层、最终用户和分销管道划分－2026-2032年全球预测

Viscosupplementation Injection Market by Product Type, Application Site, Patient Age Group, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，黏性补充剂注射剂市场价值将达到 37.2 亿美元，到 2026 年将成长至 39.8 亿美元，到 2032 年将达到 60.5 亿美元，年复合成长率为 7.17%。

关键市场统计数据
基准年 2025 37.2亿美元
预计年份：2026年 39.8亿美元
预测年份 2032 60.5亿美元
复合年增长率 (%) 7.17%

黏性补充注射疗法的简要概述：当代肌肉骨骼护理中不断发展的临床实践和相关人员的优先事项

黏液补充注射已成为多种肌肉骨骼疾病治疗方案中的重要选择，尤其适用于缓解骨关节炎的症状。这些治疗方法利用透明质酸製剂来恢復关节的黏弹性，减轻疼痛，并改善寻求全身用药和手术替代方案的患者的功能。临床医生越来越重视将黏液补充注射作为多方面治疗策略的一部分，该策略还包括物理治疗、体重管理和辅助药物治疗。这种综合观点正在改变医疗机构的关节内粘稠补充疗法模式。

检验了技术、临床实践和治疗模式方面意义深远的变革，这些变革将重新定义关节内粘稠补充疗法疗法的开发和应用方式，以及其在治疗路径中的地位。

在关节内粘稠补充疗法，引发了临床医生对作用持续时间和操作负担的更多讨论，促使他们重新评估治疗流程，并将创新疗法与传统方法相结合。同时，影像和照护现场诊断技术的进步也提高了关节内注射的准确性和可重复性，从而促进了其在诊所和门诊中心的广泛应用。

评估2025年美国关税如何重塑关节内粘稠补充疗法相关人员的供应链、采购行为和商业性韧性策略

2025年美国关税政策的实施，为关节内粘稠补充疗法生态系统的采购、供应链设计和定价动态带来了关键转折点。传统上依赖跨境进口半成品产品和成品的製造商正面临不断上涨的到岸成本和筹资策略日益严格的审查。因此，各企业正在加快近岸外包的步伐，寻找替代供应商，并优化材料清单，在确保产品完整性的前提下，优先考虑供应的连续性和合规性。

综合細項分析揭示了产品化学成分、解剖应用部位、临床环境、分销管道、价格点和患者人口统计特征如何影响产品采纳趋势和策略制定。

细分市场层面的趋势揭示了产品类型、应用部位、最终用户、分销管道、价格点和患者群体等因素对临床、采购和商业性的影响各不相同。交联和非交联透明质酸製剂之间的产品差异会影响临床医生的选择和采购谈判。交联製剂通常强调延长作用时间和增加给药频率，而非交联製剂则着重于操作简便性和成本效益。髋关节、膝关节和肩关节等不同应用部位的差异，会为临床通讯协定带来更多细微差别。特别是膝关节，需要考虑关节腔的解剖结构，例如双腔、三腔或单腔结构，这些因素会影响注射技术、证据要求和负责人训练需求。

一项区域观点，旨在揭示主要区域在法规环境、医疗服务模式和分销趋势方面的差异

区域环境对美洲、欧洲、中东和非洲以及亚太地区的临床实践模式、监管路径和商业性策略有着显着影响，每个地区都有其独特的驱动因素和限制因素。在美洲，完善的门诊医疗基础设施和日益重视的门诊服务模式支撑着诊所和门诊手术中心（ASC）手术量的成长。同时，分散的支付方要求企业集中精力进行报销工作并进行疗效评估，以确保获得有利的资金条件。在欧洲、中东和非洲地区，不同的管理体制和不均衡的报销环境要求製造商和经销商采用区域性的材料和证据包，并根据各国的医疗保健体系调整其市场进入策略。

策略竞争格局概述：重点阐述製剂创新、临床证据项目和通路伙伴关係如何定义市场差异化和长期定位。

关节内粘稠补充疗法领域的竞争格局并非简单的商品竞争，而是透过配方科学、临床证据和通路关係实现差异化。主要企业正优先建立稳固的市场地位，将专有化学技术、生产规模以及与临床研究人员的持续合作相结合。与医疗设备製造商、影像设备供应商和临床网路建立策略联盟，有助于提供整合解决方案，从而扩大市场覆盖范围并确保手术效果的一致性。此外，各公司正增加对上市后证据（包括註册研究和真实世界研究）的投入，以证明其疗效，并支持与支付方和大型机构采购方的对话。

为商业、临床和价值链领导者提供切实可行的策略蓝图，以增强韧性并加速在所有管道中采用价值主导模式。

产业领导者应采取一系列合作行动，以增强韧性、加速具有临床意义的创新并提高商业性精准度。首先，多角化采购管道和提高生产冗余度将有助于持续向大批量终端用户供应产品，同时降低贸易中断和关税波动带来的风险。其次，优先投资于长效製剂和针对特定部位需求的製剂平台，可以创造明显的临床优势，并简化患者和临床医师的治疗方法。第三，利用可靠的真实世界数据和按效果付费的合约模式与支付方合作，可以促进更广泛的药物可及性，并将商业性奖励与临床疗效挂钩。

我们以透明的方式解释我们多方面的调查方法，该方法结合了临床医生访谈、采购咨询和第二手资料整合，以确保研究结果的可靠性和检验。

这些研究结果的基础是将定性一手资料收集与严谨的二手资料分析和迭代检验相结合。一手数据包括对整形外科和风湿病临床医生、采购和供应链经理、门诊中心运营人员以及药房主任的结构化访谈，以及与临床教育工作者和支付方代表的匿名讨论，以了解报销压力和证据要求。二手资料包括同行评审的临床文献、监管指南、产品标籤以及已发布的程序和实践指南，并与一手反馈进行三角验证，以确保其与时俱进并符合临床实践。

一份简洁的策略要务概要，强调证据完整性、供应韧性和有针对性的商业化，以促进持续推广。

总之，注射用黏性补充剂在现代肌肉骨骼护理中占据战略地位，其特点是配方创新迅速、给药环境不断变化以及采购需求持续发展。将临床证据的产生与务实的经销模式和具有弹性的供应链设计相结合的相关人员，将更有利于满足临床医生的期望并应对支付方的审查。 2025年的关税环境凸显了製定更稳健的筹资策略和合约柔软性的必要性，积极应对的企业将能够在减轻短期干扰的同时，保持其长期的商业性发展势头。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 按产品类型分類的黏性补充剂注射剂市场

  • 交联玻尿酸
  • 非交联玻尿酸

9. 按应用部位分類的黏性补充剂注射剂市场

  • 髋关节
  • 膝盖
    • 双腔型
    • 三室型
    • 单人房
  • 肩关节

第十章 依患者年龄层分類的黏性补充剂注射剂市场

  • 成人
  • 老年
  • 老年人

第十一章 按最终用户分類的黏性补充剂注射剂市场

  • 门诊手术中心
  • 诊所
    • 整形外科诊所
    • 风湿病诊所
  • 医院

12. 按分销管道分類的黏性补充剂注射剂市场

  • 医院药房
  • 网路药房
  • 零售药房

13. 各地区黏性补充剂注射剂市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 黏性补充剂注射市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国黏性补充剂注射剂市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国黏性补充剂注射剂市场

第十七章：中国黏性补充剂注射剂市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Anika Therapeutics, Inc.
  • Bioiberica SAU
  • Bioventus, Inc.
  • Chugai Pharmaceutical Co., Ltd.
  • Diaco Biofarmaceutici Srl
  • Ferring Pharmaceuticals A/S
  • Fidia Farmaceutici SpA
  • Hoffmann-La Roche Ltd.
  • I+MED Srl
  • IBSA Institut Biochimique SA
  • IBSA Poland sp. z oo
  • Johnson & Johnson
  • Kyowa Hakko Kirin Co., Ltd.
  • LG Chem Ltd.
  • Maxigen Biotech Inc.
  • Ono Pharmaceutical Co., Ltd.
  • Sanofi SA
  • SEIKAGAKU CORPORATION
  • Zimmer Biomet Holdings, Inc.
Product Code: MRR-867BED9A9EDB

The Viscosupplementation Injection Market was valued at USD 3.72 billion in 2025 and is projected to grow to USD 3.98 billion in 2026, with a CAGR of 7.17%, reaching USD 6.05 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.72 billion
Estimated Year [2026] USD 3.98 billion
Forecast Year [2032] USD 6.05 billion
CAGR (%) 7.17%

Concise contextual overview of viscosupplementation injections situating clinical practice evolution and stakeholder priorities within contemporary musculoskeletal care

Viscosupplementation injections have become an integral therapeutic option within the broader musculoskeletal care pathway, particularly for symptomatic relief of osteoarthritic joints. These interventions leverage hyaluronic acid formulations to restore viscoelastic joint properties, reduce pain, and improve function in patients who may be seeking alternatives to systemic pharmacotherapy or surgical intervention. Clinicians increasingly view viscosupplementation as part of a multimodal care strategy that includes physical therapy, weight management, and adjunctive pharmacologic approaches, and this integrated perspective is reshaping adoption patterns across care settings.

At the same time, technological refinement in formulation chemistry, imaging-guided injection techniques, and delivery devices has elevated expectations for efficacy, durability, and procedural consistency. Reimbursement and procurement practices across hospitals, ambulatory surgery centers, and clinics are evolving in response to these clinical advances and the shifting preferences of patients and payors. Consequently, stakeholders from manufacturers to institution procurement teams are recalibrating product positioning, clinical education, and distribution strategies to align with contemporary clinical workflows and value-based care imperatives.

Examination of sweeping technological, clinical practice, and delivery model shifts that are redefining how viscosupplementation is developed, delivered, and positioned in care pathways

The viscosupplementation landscape is experiencing transformative shifts driven by scientific innovation, procedural diffusion, and changing healthcare delivery models. Advances in cross-linking chemistry and formulation stability have extended clinical conversations around duration of action and procedural burden, prompting clinicians to reassess treatment algorithms and integrate newer options alongside traditional modalities. Parallel to formulation innovation, improvements in imaging and point-of-care diagnostics have increased the precision and reproducibility of intra-articular injections, which in turn supports wider uptake in office-based settings and ambulatory centers.

Concurrently, service delivery is moving toward decentralized settings where ambulatory surgery centers and specialty clinics assume a larger procedural role, supported by streamlined inventory and standardized training programs. Payers and providers are also emphasizing measurable patient outcomes, driving manufacturers to invest in real-world evidence generation and registries that demonstrate sustained functional benefit. These intersecting trends are reshaping commercial models, with a clear focus on evidence-driven differentiation, channel diversification, and clinical education to support safe, consistent, and cost-effective care pathways.

Assessment of how 2025 United States tariff measures have reconfigured supply chains, procurement behavior, and commercial resilience strategies for viscosupplementation stakeholders

The introduction of United States tariffs in 2025 has created a material inflection point for procurement, supply chain design, and pricing dynamics across the viscosupplementation ecosystem. Manufacturers that historically relied on cross-border intermediate goods and finished product imports have faced elevated landed costs and increased scrutiny of sourcing strategies. As a result, organizations are accelerating nearshoring initiatives, qualifying alternative suppliers, and optimizing bill-of-materials in ways that prioritize continuity of supply and regulatory compliance without compromising product integrity.

For providers and distributors, the tariff environment has heightened the importance of contractual agility and inventory management. Hospitals and clinics are renegotiating procurement terms, extending evaluation of domestic supply options, and seeking longer-term supplier assurances to mitigate exposure to tariff-driven cost variability. From a strategic perspective, these conditions have stimulated investment in manufacturing redundancy, reshaped distribution channel economics, and intensified conversations about value-based purchasing where outcomes-linked agreements can help absorb transient input-cost shocks. Collectively, the tariff changes have forced stakeholders to be more deliberate about supplier diversification, total landed cost transparency, and the resilience of commercial contracts.

Integrated segmentation analysis illuminating how product chemistry, anatomical application, clinical setting, distribution channels, pricing tiers, and patient age cohorts shape adoption and strategy

Segment-level dynamics reveal distinct clinical, procurement, and commercial implications across product types, application sites, end users, distribution channels, price tiers, and patient age groups. Product differentiation between cross-linked hyaluronic acid and non-cross-linked formulations influences clinician choice and procurement negotiations because cross-linked chemistries generally emphasize extended residence time and dosing frequency considerations while non-cross-linked options may be positioned around procedural simplicity and cost sensitivity. Application site variation, spanning hip, knee, and shoulder interventions, further nuances clinical protocols; the knee in particular requires attention to compartmental anatomy with bicompartmental, tricompartmental, or unicompartmental designations shaping injection technique, evidence requirements, and training needs for injectors.

End-user segmentation underscores divergent purchasing behavior and procedural workflows across ambulatory surgery centers, clinics, and hospitals, with clinics requiring tailored outreach depending on whether they are orthopedic or rheumatology focused. Distribution channel distinctions are equally consequential; hospital pharmacies, online pharmacies, and retail pharmacies each present different stocking models and regulatory touchpoints, and the growth of online pharmacies-both manufacturer direct portals and third-party e-commerce platforms-has introduced new considerations around authenticity, cold chain integrity, and service-level expectations. Price-tier stratification into economy, mid tier (standard and value), and premium offerings demands a coherent value narrative that aligns clinical outcomes with cost expectations. Finally, patient age group categories-adults, elderly, and geriatric-inform product selection and communication strategies because comorbidity burden, treatment goals, and tolerability profiles shift with age. Integrating these segmentation axes enables more granular product positioning, targeted evidence generation, and channel-specific commercial plans that resonate with clinical and procurement stakeholders.

Comparative regional perspective that captures how regulatory environments, care delivery models, and distribution dynamics diverge across major global regions

Regional contexts substantially influence clinical practice patterns, regulatory pathways, and commercial approaches across the Americas, Europe, Middle East & Africa, and Asia-Pacific, each presenting unique enablers and constraints. In the Americas, robust outpatient infrastructure and a growing emphasis on ambulatory care delivery support expanded procedural volumes in clinics and ASCs, while payor fragmentation necessitates focused reimbursement engagement and outcome measurement to secure favorable procurement terms. Transitioning to Europe, Middle East & Africa, stakeholders encounter diverse regulatory regimes and heterogenous reimbursement environments, prompting manufacturers and distributors to adopt region-specific dossiers and evidence packages while calibrating market entry sequences to align with national health systems.

In the Asia-Pacific region, rapid urbanization, increased surgical capacity, and an expanding middle-aged population are driving demand for minimally invasive orthopedic interventions; however, the region also presents a complex mix of regulatory standards and local manufacturing capabilities that influence sourcing and partnership strategies. Across all regions, digital distribution channels and telehealth-enabled patient engagement are altering how education and follow-up care are delivered, and regional leadership must therefore balance global platform consistency with local customization to address clinician workflows, procurement practices, and patient expectations effectively.

Strategic competitive overview emphasizing how formulation innovation, clinical evidence programs, and channel partnerships define market differentiation and long-term positioning

Competitive dynamics in the viscosupplementation space are characterized by differentiation through formulation science, clinical evidence, and channel relationships rather than by commodity-based competition alone. Leading firms prioritize a blend of proprietary chemistry, manufacturing scale, and sustained clinical-investigator engagement to build defensible positions. Strategic alliances with device manufacturers, imaging vendors, and clinical networks amplify market reach and support integrated solutions that facilitate consistent procedural outcomes. Moreover, companies are increasingly investing in post-market evidence generation, including registries and real-world outcomes studies, to demonstrate comparative effectiveness and to support dialogue with payors and large institutional purchasers.

At the commercial interface, differentiation often hinges on the ability to provide comprehensive training, procedural support, and supply reliability to ambulatory centers and specialty clinics. Firms that can couple clinical education with streamlined distribution and transparent pricing tend to secure deeper clinical partnerships and recurring demand. Intellectual property around cross-linking methods and delivery systems can raise barriers to entry, but market incumbents must remain vigilant about biosimilar and alternative therapy developments that target specific niches. Ultimately, sustainable competitive advantage will depend on aligning R&D priorities with demonstrable clinical value and scalable commercialization pathways that reflect evolving provider and payer expectations.

Action-oriented strategic roadmap for commercial, clinical, and supply chain leaders to fortify resilience and accelerate value-driven adoption across channels

Industry leaders should pursue a coordinated set of actions that strengthen resilience, accelerate clinically meaningful innovation, and enhance commercial precision. First, diversifying sourcing and increasing manufacturing redundancy will reduce exposure to trade disruptions and tariff volatility while supporting continuity for high-volume end users. Second, prioritizing investment in longer-acting formulations and formulation platforms that address specific compartmental needs can create distinct clinical advantages and simplify treatment regimens for both patients and clinicians. Third, engaging payors with robust real-world evidence and outcomes-based contracting models can facilitate broader access and align commercial incentives with clinical effectiveness.

In parallel, companies should expand training programs that target office-based clinicians and ambulatory centers, integrating imaging best practices and standardized protocols to improve procedural consistency. Enhancing direct-to-provider and digital distribution capabilities will improve channel economics and patient access, particularly when combined with clear value propositions across economy, mid tier, and premium price points. Finally, regional go-to-market strategies should be customized to account for regulatory idiosyncrasies and procurement models, and leadership teams should implement continuous scenario planning to respond rapidly to policy or supply-chain shifts.

Transparent description of the multi-method research approach combining clinician interviews, procurement consultations, and secondary synthesis to ensure robust, validated insights

The research underpinning these insights combined qualitative primary engagement with rigorous secondary synthesis and iterative validation. Primary inputs included structured interviews with orthopedic and rheumatology clinicians, procurement and supply chain managers, ambulatory center operators, and pharmacy directors, supplemented by anonymized discussions with clinical educators and payor representatives to understand reimbursement pressures and evidence expectations. Secondary inputs consisted of peer-reviewed clinical literature, regulatory guidance, product labeling, and publicly available procedural and practice guidelines, which were triangulated against primary feedback to ensure contemporary relevance and clinical fidelity.

Data synthesis followed a layered approach: segmentation frameworks were developed and stress-tested against clinician workflows and purchaser decision criteria; thematic analysis identified recurring operational and commercial pain points; and the resultant findings were validated through follow-up consultations with key informants. Methodological limitations included variability in local reimbursement practices and the evolving nature of post-market evidence; these were mitigated by purposive sampling across regions, care settings, and stakeholder types to capture a breadth of perspectives and to surface robust, actionable conclusions.

Concise synthesis of strategic imperatives emphasizing evidence alignment, supply resilience, and targeted commercialization to drive sustainable adoption

In summary, viscosupplementation injections occupy a strategic position within contemporary musculoskeletal care, characterized by rapid formulation innovation, shifting delivery settings, and increasingly sophisticated procurement expectations. Stakeholders who align clinical evidence generation with pragmatic distribution models and resilient supply-chain designs will be best positioned to meet clinician expectations and to navigate payer scrutiny. The 2025 tariff environment has underscored the necessity for more robust sourcing strategies and contractual flexibility, and organizations that respond proactively will mitigate short-term disruption while protecting long-term commercial momentum.

Ultimately, the path forward requires coordinated investment in product differentiation, outcome measurement, and targeted commercial execution across segmented customer groups and regional contexts. By emphasizing clinician training, focused evidence programs, and tailored distribution approaches, manufacturers and channel partners can accelerate adoption where clinical need and operational readiness align, delivering improved patient experiences while meeting institutional performance and cost objectives.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Viscosupplementation Injection Market, by Product Type

  • 8.1. Cross Linked Hyaluronic Acid
  • 8.2. Non Cross Linked Hyaluronic Acid

9. Viscosupplementation Injection Market, by Application Site

  • 9.1. Hip
  • 9.2. Knee
    • 9.2.1. Bicompartmental
    • 9.2.2. Tricompartmental
    • 9.2.3. Unicompartmental
  • 9.3. Shoulder

10. Viscosupplementation Injection Market, by Patient Age Group

  • 10.1. Adults
  • 10.2. Elderly
  • 10.3. Geriatric

11. Viscosupplementation Injection Market, by End User

  • 11.1. Ambulatory Surgery Centers
  • 11.2. Clinics
    • 11.2.1. Orthopedic Clinics
    • 11.2.2. Rheumatology Clinics
  • 11.3. Hospitals

12. Viscosupplementation Injection Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Viscosupplementation Injection Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Viscosupplementation Injection Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Viscosupplementation Injection Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Viscosupplementation Injection Market

17. China Viscosupplementation Injection Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Anika Therapeutics, Inc.
  • 18.6. Bioiberica S.A.U.
  • 18.7. Bioventus, Inc.
  • 18.8. Chugai Pharmaceutical Co., Ltd.
  • 18.9. Diaco Biofarmaceutici S.r.l.
  • 18.10. Ferring Pharmaceuticals A/S
  • 18.11. Fidia Farmaceutici S.p.A.
  • 18.12. Hoffmann-La Roche Ltd.
  • 18.13. I+MED S.r.l.
  • 18.14. IBSA Institut Biochimique SA
  • 18.15. IBSA Poland sp. z o.o.
  • 18.16. Johnson & Johnson
  • 18.17. Kyowa Hakko Kirin Co., Ltd.
  • 18.18. LG Chem Ltd.
  • 18.19. Maxigen Biotech Inc.
  • 18.20. Ono Pharmaceutical Co., Ltd.
  • 18.21. Sanofi S.A.
  • 18.22. SEIKAGAKU CORPORATION
  • 18.23. Zimmer Biomet Holdings, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY APPLICATION SITE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES VISCOSUPPLEMENTATION INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CROSS LINKED HYALURONIC ACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CROSS LINKED HYALURONIC ACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CROSS LINKED HYALURONIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY NON CROSS LINKED HYALURONIC ACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY NON CROSS LINKED HYALURONIC ACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY NON CROSS LINKED HYALURONIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY HIP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY HIP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY HIP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY KNEE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY KNEE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY KNEE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY KNEE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY BICOMPARTMENTAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY BICOMPARTMENTAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY BICOMPARTMENTAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY TRICOMPARTMENTAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY TRICOMPARTMENTAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY TRICOMPARTMENTAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY UNICOMPARTMENTAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY UNICOMPARTMENTAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY UNICOMPARTMENTAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY SHOULDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY SHOULDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY SHOULDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY ELDERLY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY ELDERLY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY ELDERLY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY ORTHOPEDIC CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY ORTHOPEDIC CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY ORTHOPEDIC CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY RHEUMATOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY RHEUMATOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY RHEUMATOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY KNEE, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY KNEE, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY KNEE, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY KNEE, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY KNEE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY KNEE, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY KNEE, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY KNEE, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY KNEE, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. GCC VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GCC VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. GCC VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 143. GCC VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY KNEE, 2018-2032 (USD MILLION)
  • TABLE 144. GCC VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GCC VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. GCC VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 147. GCC VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY KNEE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY KNEE, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. G7 VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. G7 VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. G7 VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 167. G7 VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY KNEE, 2018-2032 (USD MILLION)
  • TABLE 168. G7 VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. G7 VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. G7 VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 171. G7 VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. NATO VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. NATO VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. NATO VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 175. NATO VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY KNEE, 2018-2032 (USD MILLION)
  • TABLE 176. NATO VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. NATO VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. NATO VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 179. NATO VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES VISCOSUPPLEMENTATION INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY KNEE, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY KNEE, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)